+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oligonucleotide Drug CDMO Services Market - Global Forecast 2026-2032- Product Image
Oligonucleotide Drug CDMO Services Market - Global Forecast 2026-2032- Product Image
Sale

Oligonucleotide Drug CDMO Services Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6123955
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oligonucleotide Drug CDMO Services Market is projected to reach USD 2.52 Billion in 2026. It is expected to continue growing at a CAGR of 9.47%, reaching USD 4.34 Billion by 2032.

Oligonucleotide Drug CDMO Services: Executive Overview

Oligonucleotide drug contract development and manufacturing organization (CDMO) services support the design, process development, analytical characterization, scale-up, manufacturing, and related regulatory activities required for antisense oligonucleotides, small interfering RNA, aptamers, and other nucleic-acid medicines. Demand is shaped by the expanding clinical pipeline, increasing modality complexity, strict impurity-control requirements, and the need for specialized capabilities spanning chemistry, conjugation, formulation, sterile processing, and quality assurance. The sector is therefore moving from basic synthesis support toward integrated, development-to-commercial manufacturing partnerships.

From Custom Synthesis to Integrated, Quality-Led Platforms

The operating landscape is shifting toward end-to-end programs that connect sequence design, route selection, solid-phase synthesis, purification, analytical testing, formulation, and fill-finish. Process intensification, improved purification strategies, automation, and digital batch documentation are helping address longer sequences, higher impurity burdens, and the reproducibility requirements of advanced oligonucleotide products. At the same time, sponsors are placing greater emphasis on supply continuity, technology transfer readiness, data integrity, and the ability to support both clinical and commercial quality systems.

Artificial Intelligence Accelerates Design, Development, and Manufacturing Decisions

Artificial intelligence is contributing to oligonucleotide development by supporting sequence screening, off-target assessment, synthesis-route evaluation, impurity prediction, analytical method development, and process-parameter monitoring. Machine-learning tools can help prioritize experiments and identify relationships across chromatographic, spectroscopic, and batch data, while computer vision and anomaly detection may strengthen inspection and deviation review. Adoption remains dependent on representative data, validated workflows, explainability, cybersecurity, and human oversight, particularly where algorithmic outputs influence GMP decisions or patient-facing product quality.

Regional Landscape: Specialized Capacity and Regulatory Alignment

North America combines deep pharmaceutical development activity with established analytical, regulatory, and manufacturing infrastructure. Europe benefits from strong advanced-therapy expertise, mature quality frameworks, and cross-border supply networks, while Asia-Pacific is strengthening its role through expanding pharmaceutical manufacturing capacity, technical talent, and domestic innovation. Latin America is developing capabilities around pharmaceutical production and clinical research, although access to specialized oligonucleotide infrastructure can vary. The Middle East is emphasizing life-science diversification and strategic supply resilience, and Africa remains an emerging opportunity where infrastructure investment, skills development, and regulatory capacity will be decisive.

Group Insights: Trade, Regulation, and Supply-Chain Coordination

ASEAN economies are relevant to regional manufacturing diversification and pharmaceutical supply-chain development, with capability maturity differing across members. BRICS countries provide a broad combination of scientific, manufacturing, and healthcare-system perspectives, but regulatory and infrastructure conditions are not uniform. The European Union benefits from harmonized regulatory principles alongside national implementation requirements. G7 economies generally offer advanced research, quality, and biopharmaceutical infrastructure. GCC states are pursuing healthcare and industrial diversification, while NATO members collectively represent important research, procurement, and resilience considerations, though these groupings are not equivalent regulatory markets.

Country Insights: Capabilities Differ Across Research, Manufacturing, and Regulation

The United States and Canada provide strong biotechnology ecosystems, specialized analytical capabilities, and experienced clinical-development networks. Germany, France, Italy, Spain, and the United Kingdom combine advanced pharmaceutical research with established regulatory and manufacturing expertise, while operating within distinct national and regional frameworks. China, Japan, South Korea, India, and Australia contribute growing or well-established capabilities in pharmaceutical development, chemistry, biologics, and clinical research. Brazil and Mexico are important Latin American pharmaceutical and healthcare markets, with opportunities linked to local production, technology transfer, and regulatory strengthening. Russia retains scientific and manufacturing assets, but international access, trade conditions, and supply-chain constraints materially affect collaboration considerations.

Priorities for Leaders: Build Flexible, Auditable, and Scalable Partnerships

Industry leaders should assess CDMO partners against demonstrated oligonucleotide process capability rather than general pharmaceutical capacity alone. Priority criteria include sequence and chemistry expertise, impurity control, conjugation and formulation competence, validated analytical methods, containment, sterile manufacturing where required, GMP maturity, technology-transfer discipline, and transparent capacity planning. Sponsors should establish development contracts with clearly defined data ownership, change control, comparability expectations, release responsibilities, and contingency pathways. AI initiatives should begin with narrowly governed use cases, validated data pipelines, and documented human review. Regional dual sourcing, early regulatory engagement, and lifecycle-oriented process development can further reduce execution and supply risks.

Research Methodology: Evidence-Based Market Interpretation

This executive summary uses the specified market scope-oligonucleotide drug CDMO services-and synthesizes publicly documented industry, regulatory, scientific, manufacturing, and supply-chain developments. The assessment distinguishes established capabilities from emerging opportunities and considers modality complexity, process requirements, quality systems, technology adoption, and geographic infrastructure. Regional, group, and country observations are presented as qualitative interpretations of documented conditions rather than as market estimates. No market size, share, forecast, or unverified company-specific claim is included.

Conclusion: Specialized Execution Will Define Competitive Advantage

Oligonucleotide drug CDMO services are becoming a strategic component of nucleic-acid medicine development and supply. Success will depend on combining chemistry and process depth with rigorous analytics, reliable quality systems, flexible manufacturing, secure data practices, and coordinated regulatory execution. Providers and sponsors that invest in integrated workflows, resilient capacity, responsible AI adoption, and transparent partnerships will be better positioned to manage the technical and operational demands of increasingly complex oligonucleotide programs.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oligonucleotide Drug CDMO Services Market, by Workflow Stage
7.1. Introduction
7.2. Clinical Development
7.2.1. Phase I
7.2.2. Phase II
7.2.3. Phase III
7.3. Commercial Manufacturing
7.4. Research And Development
7.4.1. Discovery
7.4.2. Preclinical
8. Oligonucleotide Drug CDMO Services Market, by Oligonucleotide Modality
8.1. Introduction
8.2. Antisense Oligonucleotides
8.2.1. Gapmers
8.2.2. Mixmers
8.2.3. Steric Blockers
8.3. Aptamers
8.3.1. DNA Aptamers
8.3.2. RNA Aptamers
8.4. CpG Oligonucleotides
8.5. MiRNA
8.6. SiRNA
9. Oligonucleotide Drug CDMO Services Market, by Production Scale
9.1. Introduction
9.2. Clinical Scale
9.3. Commercial Scale
9.4. Laboratory Scale
9.5. Pilot Scale
10. Oligonucleotide Drug CDMO Services Market, by Technology Platform
10.1. Introduction
10.2. Conjugation Technologies
10.2.1. GalNAc Conjugation
10.2.2. Lipid Nanoparticle Conjugation
10.3. Enzymatic Synthesis
10.4. Solid-Phase Synthesis
11. Oligonucleotide Drug CDMO Services Market, by Contract Model
11.1. Introduction
11.2. Integrated CDMO
11.3. Single-Service Provider
11.3.1. Analytical-Only Providers
11.3.2. Development-Only Providers
11.3.3. Manufacturing-Only Providers
12. Oligonucleotide Drug CDMO Services Market, by End User
12.1. Introduction
12.2. Academic And Research Institutes
12.3. Biopharmaceutical Companies
12.4. Pharmaceutical Companies
13. Oligonucleotide Drug CDMO Services Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Oligonucleotide Drug CDMO Services Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Oligonucleotide Drug CDMO Services Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AGC Biologics, Inc.
17.2. Alcami Corporation
17.3. Catalent, Inc.
17.4. CordenPharma International GmbH
17.5. Eurofins Scientific
17.6. GenScript Biotech Corporation
17.7. Kaneka Eurogentec S.A.
17.8. Lonza Group Ltd.
17.9. Merck KGaA
17.10. Patheon Manufacturing Services LLC
17.11. Samsung Biologics Co., Ltd.
17.12. Thermo Fisher Scientific, Inc.
17.13. WuXi AppTec Co., Ltd.
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Oligonucleotide Drug CDMO Services Market, Years Considered for the Study
FIGURE 2. Global Oligonucleotide Drug CDMO Services Market, Research Design
FIGURE 3. Global Oligonucleotide Drug CDMO Services Market, Research Framework
FIGURE 4. Global Oligonucleotide Drug CDMO Services Market, Data Triangulation
FIGURE 5. Global Oligonucleotide Drug CDMO Services Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2025 vs 2032 (%)
FIGURE 7. Global Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2025 vs 2032 (%)
FIGURE 9. Global Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2025 vs 2032 (%)
FIGURE 11. Global Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 13. Global Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2025 vs 2032 (%)
FIGURE 15. Global Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Oligonucleotide Drug CDMO Services Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Oligonucleotide Drug CDMO Services Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Oligonucleotide Drug CDMO Services Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Oligonucleotide Drug CDMO Services Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Oligonucleotide Drug CDMO Services Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Oligonucleotide Drug CDMO Services Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Oligonucleotide Drug CDMO Services Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Oligonucleotide Drug CDMO Services Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Oligonucleotide Drug CDMO Services Market Segmentation & Coverage
TABLE 2. Global Oligonucleotide Drug CDMO Services Market Size, 2017-2032 (USD Million)
TABLE 3. Global Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 4. Global Clinical Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Clinical Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Clinical Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Research And Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Research And Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Research And Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Discovery Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Discovery Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Discovery Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 29. Global Antisense Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Antisense Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Antisense Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Gapmers Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Gapmers Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Gapmers Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Mixmers Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Mixmers Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Mixmers Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Steric Blockers Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Steric Blockers Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Steric Blockers Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Aptamers Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Aptamers Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Aptamers Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global DNA Aptamers Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global DNA Aptamers Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global DNA Aptamers Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global RNA Aptamers Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global RNA Aptamers Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global RNA Aptamers Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global CpG Oligonucleotides Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global CpG Oligonucleotides Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global CpG Oligonucleotides Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global MiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global MiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global MiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global SiRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global SiRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global SiRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 60. Global Clinical Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Clinical Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Clinical Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Commercial Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Commercial Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Commercial Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Laboratory Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Laboratory Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Laboratory Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Pilot Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Pilot Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Pilot Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 73. Global Conjugation Technologies Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Conjugation Technologies Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Conjugation Technologies Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global GalNAc Conjugation Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global GalNAc Conjugation Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global GalNAc Conjugation Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Lipid Nanoparticle Conjugation Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Lipid Nanoparticle Conjugation Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Lipid Nanoparticle Conjugation Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Enzymatic Synthesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Enzymatic Synthesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Enzymatic Synthesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Solid-Phase Synthesis Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Solid-Phase Synthesis Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Solid-Phase Synthesis Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 89. Global Integrated CDMO Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Integrated CDMO Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Integrated CDMO Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Single-Service Provider Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Global Single-Service Provider Market Size, by Group, 2017-2032 (USD Million)
TABLE 94. Global Single-Service Provider Market Size, by Country, 2017-2032 (USD Million)
TABLE 95. Global Analytical-Only Providers Market Size, by Region, 2017-2032 (USD Million)
TABLE 96. Global Analytical-Only Providers Market Size, by Group, 2017-2032 (USD Million)
TABLE 97. Global Analytical-Only Providers Market Size, by Country, 2017-2032 (USD Million)
TABLE 98. Global Development-Only Providers Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. Global Development-Only Providers Market Size, by Group, 2017-2032 (USD Million)
TABLE 100. Global Development-Only Providers Market Size, by Country, 2017-2032 (USD Million)
TABLE 101. Global Manufacturing-Only Providers Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Global Manufacturing-Only Providers Market Size, by Group, 2017-2032 (USD Million)
TABLE 103. Global Manufacturing-Only Providers Market Size, by Country, 2017-2032 (USD Million)
TABLE 104. Global Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 105. Global Academic And Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 106. Global Academic And Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 107. Global Academic And Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 108. Global Biopharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 109. Global Biopharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. Global Biopharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 111. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 112. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 113. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 114. Global Oligonucleotide Drug CDMO Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 115. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 128. North America Oligonucleotide Drug CDMO Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. North America Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 130. North America Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 131. North America Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 132. North America Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 133. North America Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 134. North America Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 135. North America Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 136. North America Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 137. North America Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 138. North America Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 139. North America Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 140. North America Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 141. Latin America Oligonucleotide Drug CDMO Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 142. Latin America Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 143. Latin America Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 144. Latin America Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 145. Latin America Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 146. Latin America Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 147. Latin America Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 148. Latin America Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 149. Latin America Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 150. Latin America Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 151. Latin America Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 152. Latin America Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 153. Latin America Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 154. Europe Oligonucleotide Drug CDMO Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 155. Europe Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 156. Europe Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 157. Europe Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 158. Europe Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 159. Europe Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 160. Europe Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 161. Europe Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 162. Europe Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 163. Europe Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 164. Europe Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 165. Europe Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 166. Europe Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 167. Middle East Oligonucleotide Drug CDMO Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 168. Middle East Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 169. Middle East Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 170. Middle East Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 171. Middle East Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 172. Middle East Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 173. Middle East Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 174. Middle East Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 175. Middle East Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 176. Middle East Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 177. Middle East Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 178. Middle East Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 179. Middle East Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. Africa Oligonucleotide Drug CDMO Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Africa Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 182. Africa Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 183. Africa Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 184. Africa Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 185. Africa Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 186. Africa Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 187. Africa Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 188. Africa Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 189. Africa Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 190. Africa Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 191. Africa Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 192. Africa Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 193. Global Oligonucleotide Drug CDMO Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 194. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 196. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 197. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 198. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 199. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 200. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 201. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 202. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 203. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 204. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 205. ASEAN Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 206. ASEAN Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 207. GCC Oligonucleotide Drug CDMO Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 208. GCC Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 209. GCC Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 210. GCC Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 211. GCC Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 212. GCC Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 213. GCC Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 214. GCC Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 215. GCC Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 216. GCC Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 217. GCC Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 218. GCC Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 219. GCC Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 220. European Union Oligonucleotide Drug CDMO Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. European Union Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 222. European Union Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 223. European Union Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 224. European Union Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 225. European Union Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 226. European Union Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 227. European Union Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 228. European Union Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 229. European Union Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 230. European Union Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 231. European Union Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 232. European Union Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 233. BRICS Oligonucleotide Drug CDMO Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 234. BRICS Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 235. BRICS Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 236. BRICS Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 237. BRICS Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 238. BRICS Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 239. BRICS Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 240. BRICS Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 241. BRICS Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 242. BRICS Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 243. BRICS Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 244. BRICS Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 245. BRICS Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 246. G7 Oligonucleotide Drug CDMO Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 247. G7 Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 248. G7 Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 249. G7 Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 250. G7 Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 251. G7 Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 252. G7 Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 253. G7 Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 254. G7 Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 255. G7 Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 256. G7 Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 257. G7 Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 258. G7 Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 259. NATO Oligonucleotide Drug CDMO Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 260. NATO Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 261. NATO Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 262. NATO Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 263. NATO Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 264. NATO Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 265. NATO Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 266. NATO Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 267. NATO Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 268. NATO Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 269. NATO Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 270. NATO Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 271. NATO Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Global Oligonucleotide Drug CDMO Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 273. United States Oligonucleotide Drug CDMO Services Market Size, 2017-2032 (USD Million)
TABLE 274. United States Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 275. United States Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 276. United States Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 277. United States Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 278. United States Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 279. United States Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 280. United States Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 281. United States Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 282. United States Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 283. United States Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 284. United States Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 285. United States Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 286. Canada Oligonucleotide Drug CDMO Services Market Size, 2017-2032 (USD Million)
TABLE 287. Canada Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 288. Canada Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 289. Canada Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 290. Canada Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 291. Canada Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 292. Canada Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 293. Canada Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 294. Canada Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 295. Canada Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 296. Canada Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 297. Canada Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 298. Canada Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 299. Mexico Oligonucleotide Drug CDMO Services Market Size, 2017-2032 (USD Million)
TABLE 300. Mexico Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 301. Mexico Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 302. Mexico Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 303. Mexico Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 304. Mexico Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides, 2017-2032 (USD Million)
TABLE 305. Mexico Oligonucleotide Drug CDMO Services Market Size, by Aptamers, 2017-2032 (USD Million)
TABLE 306. Mexico Oligonucleotide Drug CDMO Services Market Size, by Production Scale, 2017-2032 (USD Million)
TABLE 307. Mexico Oligonucleotide Drug CDMO Services Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 308. Mexico Oligonucleotide Drug CDMO Services Market Size, by Conjugation Technologies, 2017-2032 (USD Million)
TABLE 309. Mexico Oligonucleotide Drug CDMO Services Market Size, by Contract Model, 2017-2032 (USD Million)
TABLE 310. Mexico Oligonucleotide Drug CDMO Services Market Size, by Single-Service Provider, 2017-2032 (USD Million)
TABLE 311. Mexico Oligonucleotide Drug CDMO Services Market Size, by End User, 2017-2032 (USD Million)
TABLE 312. Brazil Oligonucleotide Drug CDMO Services Market Size, 2017-2032 (USD Million)
TABLE 313. Brazil Oligonucleotide Drug CDMO Services Market Size, by Workflow Stage, 2017-2032 (USD Million)
TABLE 314. Brazil Oligonucleotide Drug CDMO Services Market Size, by Clinical Development, 2017-2032 (USD Million)
TABLE 315. Brazil Oligonucleotide Drug CDMO Services Market Size, by Research And Development, 2017-2032 (USD Million)
TABLE 316. Brazil Oligonucleotide Drug CDMO Services Market Size, by Oligonucleotide Modality, 2017-2032 (USD Million)
TABLE 317. Brazil Oligonucleotide Drug CDMO Services Market Size, by Antisense Oligonucleotides,

Companies Mentioned

  • AGC Biologics, Inc.
  • Alcami Corporation
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Eurofins Scientific
  • GenScript Biotech Corporation
  • Kaneka Eurogentec S.A.
  • Lonza Group Ltd.
  • Merck KGaA
  • Patheon Manufacturing Services LLC
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec Co., Ltd.

Related Topics

Related Reports

Antibody-Oligonucleotide Conjugates Drug CDMO Market - Global Forecast 2026-2032 - Product Image

Antibody-Oligonucleotide Conjugates Drug CDMO Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 150 Pages
  • Global
From
Oligonucleotide CDMO Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035 - Product Image

Oligonucleotide CDMO Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

  • Report
  • 154 Pages
  • Global
From
Peptide and Oligonucleotide CDMO - Global Strategic Business Report - Product Image

Peptide and Oligonucleotide CDMO - Global Strategic Business Report

  • Report
  • 370 Pages
  • Global
From
Peptide and Oligonucleotide CDMO Market Report 2026 - Product Image

Peptide and Oligonucleotide CDMO Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.